PSA test losing value in predicting prostate cancer
The value of the prostate-specific antigen (PSA) test as a diagnostic tool for prostate cancer has declined following changes in medical practice, according to a new study. Study author Dr. Douglas S. Scherr said that the PSA test is still very predictive in men with an abnormal digital rectal examination, while for men with a normal digital rectal examination, the test’s predictive accuracy has declined. For the latter category of men, doctors are opting for biopsies and are using improved biopsy techniques.
- Proteins HE4, CA 125 key to predicting ovarian cancer
- FDA clearance to Ikonisys’ oncoFISH HER2 test
- New approach eliminates post-surgery pain
- Massage can help advanced cancer patients
